Landmark Research Studies
completed

COMPASS was a randomized controlled trial that discovered that the use of rivaroxaban, a new antithrombotic treatment, reduces heart attacks, strokes, amputations and death in patients with coronary artery disease (CAD) or peripheral arterial disease (PAD).

Findings of the COMPASS trial resulted in regulatory approval of rivaroxaban for CAD and PAD by regulators around the world.

Primary efficacy outcome:

Time from randomization to the first occurrence of either myocardial infarction, stroke, or cardiovascular death, over approximately five years.

Primary safety outcome:

Time from randomization to the first occurrence of major bleeding (modified International Society on Thrombosis and Haemostasis), over approximately five years.

The randomized trial is complete; the open label extension of COMPASS is ongoing.

COMPASS Overview - Download PDF
Study Type

Interventional - Drug

Study Design

RCT double-blind

NO. of Countries

33

NO. of Sites

602

NO. of Participants

27395

Study Period

2013 - 2017

Sponsor

Bayer

VIDEO: Salim Yusuf, Sonia Anand and John Eikelboom discuss COMPASS

VIDEO: John Eikelboom on COMPASS at ESC 2017

VIDEO: Pantoprazole to Prevent Upper GI Events - COMPASS

Bayer

Janssen Research & Development

Back To Top